Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Figures & data

Figure 1 Color matrix showing OS benefit or lack of benefit by stage among the large adjuvant platinum-based chemotherapy or other adjuvant chemotherapy versus observation. Red box indicated no OS benefit. Yellow box indicated OS benefit determined retrospectively or OS did not persist overtime. Green box indicated OS benefit. White box indicated that particular stage was not investigated in the trial.

Abbreviations: ALPI, Adjuvant Lung Cancer Project Italy; ANITA, Adjuvant Navelbine International Trialist Association; BLT, Big Lung Trial; CALGB, Cancer and Leukemia Group B; IALT, International Adjuvant Lung Trial.

Figure 2 Bar-charts showing the percentage of patients who received adjuvant chemotherapy by stage (IB, II, III) and by treatment arms (Osimertinib, placebo).

Figure 3 Side by side comparison of 2-year Disease-free survival (DFS) by treatment arms according to stage.

Table 1 Percentages of Patients Completed the Full Planned Adjuvant Platinum-Based Chemotherapy

Trial Name	Percentage of Patients Completed the Total Planned Cycles of Chemotherapy
Unselected NSCLC
ALPI	69% (50.6% required dose delay or reduction)
IALT	73.8% received total of 240 mg/m2 of cisplatin (reference for JBR-10 and ANITA is 400 mg/m2)
JBR-10	45% randomized; 48% treated
ANITA	50%
BLT	64% (40% required dose delay and/or reduction)
CALGB 9633	21% of patient with no chemotherapy completion data; otherwise, 86% of the patients with known chemotherapy data received all 4 cycles (34% required dose delay or interruption)
ITACA	Tailored group: Cisplatin/pemetrexed (79.5%); cisplatin/gemcitabine (69.2%) Control group: cisplatin-based regimens (~66%)
EGFR+ NSCLC
ADJUVANT	66.4% of intention-to-treat population; 84% of patients who received chemotherapy
EVIDENCE	68%
IMPACT	78%
EVAN (phase 2)	62.7% of Intention-to-treat population; 74.4% of patients who received chemotherapy